Verastem Oncology to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
May 16 2019 - 7:00AM
Business Wire
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company),
focused on developing and commercializing medicines seeking to
improve the survival and quality of life of cancer patients, today
announced that the Company will present at the 20th Annual B. Riley
FBR Institutional Investor Conference on Thursday, May 23, 2019 at
1:30 p.m. PDT in Beverly Hills, CA.
A live webcast of the presentation will be available on the
investors section of the Company’s website at www.verastem.com. An
archived presentation will be available for 90 days.
About Verastem Oncology
Verastem Oncology (Nasdaq:VSTM) is a commercial
biopharmaceutical company committed to the development and
commercialization of medicines to improve the lives of patients
diagnosed with cancer. We are driven by the strength, tenacity and
courage of those battling cancer – single-minded in our resolve to
deliver new therapies that not only keep cancer at bay, but improve
the lives of patients diagnosed with cancer. Because for us, it’s
personal.
Our first FDA approved product is now available for the
treatment of patients with certain types of indolent non-Hodgkin’s
lymphoma (iNHL). Our pipeline comprises product candidates that
seek to treat cancer by modulating the local tumor
microenvironment. For more information, please visit
www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190516005067/en/
Verastem Oncology:John DoyleVice President, Investor Relations
& Finance+1 781-469-1546jdoyle@verastem.comInvestors:Joseph
RayneArgot Partners+1 617-340-6075joseph@argotpartners.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Sep 2023 to Sep 2024